Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $18.8052W HIGH $36.66
Volume
1.95 M
Value Traded
70.90 M
Short % Float
8.68%
Days to Cover
3.9
0%Week
+0.36%1 Month
+56.88%3 Month
+62.48%6 Month
-65.11%5 Year
+233.57%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.45 B
EPS (TTM)
0.95
P/E Ratio
38.57
Ent. Value
1.45 B
Total Shares
39.86 M
Float Shares
38.59 M
Insiders
3.75%
Institutions
108.45%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
PCRX Catalyst Timeline
Dated clinical, regulatory and corporate events for Pacira BioSciences, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Pacira BioSciences, Inc.
495Total events
16Upcoming
112Tier-1 (high impact)
2016 to 2031Coverage
Upcoming catalysts 2
Event history 50
▲Partnership / LicenseExparelApprovedCorporate
Pacira grants Molteni Farmaceutici exclusive rights to commercialize EXPAREL in the EU and UK
postsurgical pain managementsource ↗
●Grant / FundingCorporate
Pacira grants inducement stock options and RSUs to two new employees
▲Full ResultsPCRX-201Clinical Data
Two-year Phase 1 data published in Annals of the Rheumatic Diseases
knee osteoarthritissource ↗
▲Trial InitiationPCRX-201Trial
Initiated enrollment in Part B of Phase 2 ASCEND study
knee osteoarthritissource ↗
▲Manufacturing MilestonePCRX-201CMC / Inspection
Successful transition to scalable manufacturing process
◆Enrollment UpdatePCRX-201Trial
Enrollment underway in Part B of Phase 2 ASCEND study
osteoarthritis of the kneesource ↗
▲Manufacturing MilestonePCRX-201CMC / Inspection
PCRX-201 transitions to scalable commercial manufacturing process
osteoarthritis of the kneesource ↗
▲PublicationPCRX-201Presentation
Phase 1 study of PCRX-201 accepted for publication in Annals of the Rheumatic Diseases
osteoarthritis of the kneesource ↗
▲REMS ModifiedExparelApprovedPost-Market
UnitedHealthcare now provides separate reimbursement for EXPAREL
●Runway Guidance UpdateCorporate
Pacira updates full-year 2026 guidance due to iovera° divestiture
▲Acquisitioniovera°FiledCorporate
Pacira completes divestiture of iovera° business to Zimmer Biomet
▲Partnership / Licenseiovera°FiledCorporate
Pacira and Zimmer Biomet to collaborate on spasticity program
▲First Patient DosedPCRX-201Trial
First patient enrolled in Part B of Phase 2 ASCEND study
osteoarthritis of the kneesource ↗
▲Manufacturing MilestonePCRX-201CMC / Inspection
Transition to scalable commercial manufacturing process completed
osteoarthritis of the kneesource ↗
▲Quarterly UpdateExparelApprovedCorporate
UnitedHealthcare provides separate reimbursement for EXPAREL across outpatient settings
postsurgical pain managementsource ↗
◆Other Regulator MilestoneExparelApprovedEx-US Regulatory
LG Chem plans to file for marketing authorizations in South Korea and Thailand
postsurgical pain managementsource ↗
▲Partnership / LicenseCorporate
Collaboration on advancing spasticity program with Zimmer Biomet
spasticitysource ↗
◆Oral PresentationPresentation
Pacira to participate in Goldman Sachs 47th Annual Global Healthcare Conference fireside chat
◆Oral PresentationPresentation
Pacira to participate in Jefferies Global Healthcare Conference fireside chat
▲Enrollment CompletePCRX-201Trial
Enrollment in Part A of Phase 2 ASCEND study concluded
osteoarthritis of the kneesource ↗
▲Patent GrantedIP / Competition
Pacira filed 21 Orange Book-listed patents across two families
▲Patent GrantedExparelApprovedIP / Competition
21 Orange Book listed patents across two families
◆Oral PresentationPresentation
Pacira to participate in RBC Capital Markets Global Healthcare Conference fireside chat
▲IP Litigation RulingExparelApprovedIP / Competition
Favorable volume-limited settlement in EXPAREL patent litigation securing exclusivity through 2030
postsurgical painsource ↗
▲Equity OfferingCorporate
$200 million returned to stockholders under $300 million share repurchase program since April 2025
▲Oral PresentationExparelApprovedPresentation
Real-world study of EXPAREL in TSA presented at ISPOR 2026
total shoulder arthroplastysource ↗
▲Enrollment CompleteZILRETTAApprovedTrial
Completed enrollment of Phase 3 study of ZILRETTA in shoulder OA
shoulder osteoarthritissource ↗
▲Poster PresentationExparelApprovedPresentation
Poster presentation of real-world data on EXPAREL at ASRA Annual Meeting
postoperative pain following outpatient total hip arthroplastysource ↗
◆Oral PresentationPresentation
Fireside chat at 25th Annual Needham Virtual Healthcare Conference
▲Poster PresentationExparelApprovedPresentation
Poster #363: Real-World Assessment of Healthcare Expenditures and Opioid Intake Following Total Hip Arthroplasty in Medicare Advantage Beneficiaries
Total Hip Arthroplastysource ↗
▲Enrollment CompleteZILRETTAApprovedTrial
Completed enrollment in Phase 3 registrational study of ZILRETTA in shoulder OA
osteoarthritis pain of the shouldersource ↗
▲Oral PresentationExparelApprovedPresentation
Presented real-world EXPAREL data at Academy of Managed Care Pharmacy Annual 2026 Meeting
total hip arthroplasty and total knee arthroplastysource ↗
◆Poster PresentationExparelApprovedPresentation
Poster presentation on costs and healthcare resource utilization of liposomal bupivacaine vs ropivacaine in TKA
total knee arthroplastysource ↗
◆Oral PresentationPresentation
Fireside chat at Barclays 28th Annual Global Healthcare Conference
▲Poster PresentationExparelApprovedPresentation
Poster presentation: Intraoperative Liposomal Bupivacaine Is Associated With Improved Pain, Opioid Use, Functional, and Length of Stay Outcomes After Total Knee Arthroplasty: Real-world Evidence
total knee arthroplastysource ↗
▲Poster Presentationiovera°FiledPresentation
Poster presentation: Cryoneurolysis for Knee Osteoarthritis in a Real-World Registry: Pain and Functional Outcomes over 12 Months
knee osteoarthritissource ↗
▲Oral PresentationExparelApprovedPresentation
Presented IGOR registry data on EXPAREL for TKA at American Academy of Orthopedic Surgeons 2026 Annual Meeting
total knee arthroplastysource ↗
▲Oral Presentationiovera°FiledPresentation
Presented IGOR registry data on iovera° for OA knee at American Academy of Orthopedic Surgeons 2026 Annual Meeting
osteoarthritis of the kneesource ↗
◆Quarterly UpdateCorporate
Q4 and full year 2025 financial results release and conference call
◆Oral PresentationPresentation
Pacira BioSciences to present at 44th Annual J.P. Morgan Healthcare Conference
Past FDA Catalysts and PDUFA Decisions
How PCRX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2023-11-09 | Exparel (bupivacaine) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
4
Drugs Scored
rNPV / MCap
Top Drug
Top 17%
Micro Cap(rank 118 of 687)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Sep 2026; product lines: last four quarters to Sep 2026 (10-K and 10-Q))
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| EXPAREL | |||
| ZILRETTA | |||
| iovera° | |||
| Bupivacaine liposome injectable suspension |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Enekinragene Inzadenovec Gene TherapiesNCT06884865 | Osteoarthritis (OA) of the Knee | Phase 2 | RECRUITING | 135 | Jul 1, 2032 | ||||||
| FX201 Gene TherapiesNCT04119687 | Osteoarthritis, Knee | Phase 1 | ACTIVE NOT_RECRUITING | 72 | Nov 28, 2026 | ||||||
| ZILRETTA Small MoleculesNCT06269705 | Glenohumeral Osteoarthritis | Phase 3 | ACTIVE NOT_RECRUITING | 150 | Dec 1, 2026 | ||||||
| FX006 Small MoleculesCompletedNCT03529942 | Osteoarthritis, Knee | Phase 3 | COMPLETED | 129 | Mar 9, 2020 | ||||||
| FX006 Small MoleculesCompletedNCT02116972 | Osteoarthritis of the Knee | Phase 3 | COMPLETED | 1,421 | Nov 1, 2015 | ||||||
| FX006 Small MoleculesCompletedNCT03378076 | Bilateral Knee Osteoarthritis | Phase 2 | COMPLETED | 24 | Mar 14, 2018 | ||||||
| FX006 Small MoleculesCompletedNCT03382262 | Osteoarthritis of the Shoulder | Phase 2 | COMPLETED | 55 | Oct 9, 2018 | ||||||
| FX006 Small MoleculesCompletedNCT04065074 | Osteoarthritis, Hip | Phase 2 | COMPLETED | 16 | Dec 30, 2019 | ||||||
| Liposomal Bupivacaine 13.3 Small MoleculesCompletedNCT05456490 | Undisclosed | Phase 1 | COMPLETED | 54 | Feb 27, 2025 | ||||||
| FX301 Small MoleculesCompletedNCT04826328 | Pain, Postoperative | Phase 1 | COMPLETED | 85 | Mar 30, 2022 | ||||||
| Exparel Small MoleculesNot countedNCT05139030 | Knee Osteoarthritis | Phase 3 | COMPLETED | 167 | Jul 11, 2022 | ||||||
| Exparel Small MoleculesNot countedNCT05157841 | Bunionectomy | Phase 3 | COMPLETED | 185 | Aug 17, 2022 | ||||||
| Exparel Small MoleculesNot countedNCT04518462 | Lower Extremity Surgery | Phase 3 | COMPLETED | 121 | Apr 5, 2021 | ||||||
| SKY0402 Small MoleculesNot countedNCT00890682 | Bunion | Phase 3 | COMPLETED | 193 | Nov 1, 2009 | ||||||
| Exparel Small MoleculesNot countedNCT05171179 | Mammaplasty | Phase 3 | COMPLETED | 60 | Jul 1, 2025 | ||||||
| SKY0402 Small MoleculesNot countedNCT00744848 | Hemorrhoid | Phase 3 | COMPLETED | 393 | Feb 1, 2009 | ||||||
| SKY0402 Small MoleculesMarketedNCT00485667 | Postoperative Pain | Approved | COMPLETED | 727 | Aug 1, 2007 | ||||||
| Exparel Small MoleculesMarketedNCT03485014 | Postoperative Pain Management | Approved | COMPLETED | 113 | Feb 12, 2019 | ||||||
| Exparel Small MoleculesMarketedNCT01683071 | Postoperative Pain | Approved | COMPLETED | 495 | Dec 1, 2013 | ||||||
| Exparel Small MoleculesNot countedNCT01802411 | Posterolateral Thoracotomy | Phase 3 | COMPLETED | 191 | Jun 1, 2013 | ||||||
| Exparel Small MoleculesMarketedNCT02713230 | Pain | Approved | COMPLETED | 388 | Jul 7, 2017 | ||||||
| Bupivacaine liposome Small MoleculesNot countedNCT02517905 | Dental Pain | Phase 3 | COMPLETED | 166 | Jan 1, 2016 | ||||||
| Exparel Injectable Product Small MoleculesNot countedNCT03270514 | Coronary Artery Disease | Phase 3 | COMPLETED | 60 | Feb 25, 2020 | ||||||
| SKY0402 Small MoleculesNot countedNCT01203644 | Inguinal Hernia | Phase 2 | COMPLETED | 76 | Dec 1, 2006 | ||||||
| Triamcinolone Acetonide Injectable Small MoleculesMarketedNCT04261049 | Osteoarthritis, Knee | Approved | COMPLETED | 35 | Jan 10, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every PCRX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| PCRX-201 RMAT | knee osteoarthritis | Phase 1 | 2026-08-06 | improvements out to two years in pain, stiffness, and function across all doses and groupsRead More | Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic DiseasesRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| RIKER LAURENOfficer (Senior Vice President, Finance) | Option | 6,000 68,284.242 held | $32.35 | 10/08/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PCRX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 0.6 % | 10.93 M | 457.47 K |
Ownership Trends
PCRX Short Interest
Shares sold short, counted twice a month.
8.68%
Short % of Float
of tradable shares sold short
3.3M
Shares Sold Short
-21.4% vs prior count
3.9 Moderate
Days to Cover
trading days of normal volume to buy every short share back
855.6K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PCRX ranks across every disease it competes in
Competitive Position is a premium feature
See how PCRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPCRX News
PCRXPacira BioSciences and Caregiver Action Network Announce New Survey on Gaps in Preparing Families for Postsurgical Recovery at Home
Pacira BioSciences and Caregiver Action Network conducted a survey revealing that caregivers feel inadequately prepared for managing postsurgical recovery at home. The survey showed that caregivers desire clearer pain management plans and more information on non-opioid options. Many respondents expressed concerns about medication administration and the lack of support during the hospital-to-home transition. The findings emphasize the need for better caregiver education and resources before surgery.
Read more →PCRXPacira Announces Exclusive Agreement with Molteni Farmaceutici to Commercialize EXPAREL® in the European Union and United Kingdom
Pacira BioSciences has entered a strategic partnership with Molteni Farmaceutici to commercialize EXPAREL in the European Union and United Kingdom. This agreement aims to enhance patient access to opioid-sparing pain management solutions. Molteni will manage regulatory and commercialization efforts, with the first sales anticipated in 2027. The partnership aligns with Pacira's growth strategy.
Read more →PCRXPacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pacira BioSciences announced the granting of inducement awards to five new employees as part of its Amended and Restated 2014 Inducement Plan. The awards include stock options and restricted stock units, approved by the People & Compensation Committee without stockholder approval. This move aims to enhance the company's workforce and align employee interests with the company's performance.
Read more →PCRXPacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases
Pacira BioSciences announced positive two-year results from its Phase 1 trial of PCRX-201, a gene therapy for knee osteoarthritis. The study demonstrated that a single intra-articular injection was well tolerated, with significant improvements in pain, stiffness, and function. The company is now advancing PCRX-201 into Phase 2 clinical development, with topline results expected by the end of 2026.
Read more →PCRX▼ -10%on this newsshared move
Pacira BioSciences Reports Second Quarter 2026 Financial Results
Pacira BioSciences reported a strong second quarter in 2026, achieving total revenues of $192.4 million, a 6% increase from the previous year. The company successfully divested its iovera business to Zimmer Biomet, which is expected to enhance its focus on innovation. Additionally, the reimbursement for EXPAREL by UnitedHealthcare marks a significant step in expanding access to non-opioid pain management. However, the company noted an increase in operating expenses and a decrease in non-GAAP net income compared to the prior year.
Read more →PCRXPacira BioSciences Announces New National Survey Revealing the Hidden Toll of Pain on America’s Workforce
Pacira BioSciences has released findings from a national survey highlighting the significant impact of orthopedic pain, particularly knee pain, on America's workforce. The survey indicates that a majority of workers experience pain that affects their income and career prospects. Additionally, there is a strong preference for long-lasting, non-opioid pain management options among those suffering from chronic pain.
Read more →PCRXPacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process
Pacira BioSciences has successfully transitioned its investigational gene therapy PCRX-201 to a scalable commercial manufacturing process, enabling the enrollment of the first patient in Part B of the Phase 2 ASCEND study. The company anticipates topline data from Part A by the end of 2026, further supporting its growth strategy and the therapy's potential for treating osteoarthritis of the knee.
Read more →PCRXPacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026
Pacira BioSciences, Inc. will report its second quarter 2026 financial results on August 4, 2026, after U.S. market close. A live conference call and webcast will follow at 4:30 p.m. ET, allowing for a question and answer session. Interested participants can pre-register for the call and access a replay on the company's website.
Read more →PCRXPacira BioSciences Joins Life Science Cares as National Corporate Partner
Pacira BioSciences has partnered with Life Science Cares as a National Corporate Partner to enhance community support across major life science hubs. The collaboration focuses on addressing poverty and inequality through financial contributions and employee volunteer efforts. This initiative highlights the importance of corporate social responsibility in the life sciences sector.
Read more →PCRXPacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®
Pacira BioSciences announced that UnitedHealthcare will now provide separate reimbursement for EXPAREL, enhancing patient access to non-opioid postsurgical pain management. This decision allows EXPAREL to be reimbursed outside of surgical bundles, benefiting eligible UnitedHealthcare members. With this change, around 150 million covered lives now have access to this treatment, promoting safer pain management alternatives.
Read more →PCRXPacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet
Pacira BioSciences has announced the divestiture of its iovera° business to Zimmer Biomet for up to $140 million, including an upfront payment of $70 million. This move aligns with Pacira's strategy to transition into an innovative biopharmaceutical company. The two companies will collaborate on advancing a spasticity program, with potential future milestone payments based on revenue.
Read more →PCRXPacira BioSciences Announces Stockholders Have Elected All Three of the Company's Director Nominees at Annual Meeting
Pacira BioSciences announced that all three of its director nominees were elected at the 2026 Annual Meeting of Stockholders. The nominees include Christopher Christie, Samit Hirawat, MD, and Thomas Wiggans. CEO Frank D. Lee expressed gratitude to stockholders for their trust and highlighted the company's commitment to its growth strategy. Final results will be certified and reported in a Current Report on Form 8-K.
Read more →PCRXPacira BioSciences Reminds Stockholders to Vote the BLUE Proxy Card "FOR" the Election of the Company's Highly Qualified Nominees Ahead of its Annual Meeting
Pacira BioSciences is urging stockholders to vote for its director nominees ahead of the 2026 Annual Meeting. The company highlights its successful 5x30 strategy and strong financial performance, with endorsements from leading proxy advisory firms recommending support for its nominees. In contrast, it warns against the potential negative impact of DOMA's nominees on its growth.
Read more →PCRXPacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director Nominees
Pacira BioSciences received a positive recommendation from ISS to vote for its director nominees ahead of the 2026 Annual Meeting. ISS highlighted the company's improved performance and proactive governance under its current board. In contrast, ISS criticized DOMA's nominees for lacking relevant experience and presenting an unconvincing case for change. Pacira urges stockholders to support its nominees and disregard DOMA's proxy card.
Read more →PCRXLeading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Pacira’s Director Nominees
Pacira BioSciences received a positive recommendation from Glass Lewis to vote for its director nominees ahead of the 2026 Annual Meeting. The advisory firm highlighted Pacira's strong stockholder returns and the effectiveness of its 5x30 strategy. Glass Lewis also criticized DOMA Perpetual's nominees, questioning their capability to implement a transformative strategic review.
Read more →PCRXPacira BioSciences Reports Real-World Study Showing EXPAREL® Use Was Associated with Reduced Opioid Use and Healthcare Costs in Patients Undergoing Total Shoulder Arthroplasty
Pacira BioSciences announced findings from a real-world study showing that the use of EXPAREL after total shoulder arthroplasty resulted in lower opioid consumption, reduced healthcare costs, and fewer opioid-related adverse events. The study, presented at ISPOR 2026, involved over 6,400 Medicare Advantage patients and highlights the importance of non-opioid pain management strategies amidst rising surgical procedures.
Read more →PCRXPacira BioSciences Mails Letter to Stockholders Reiterating Confidence in the Company’s Strategic Direction and Highly Qualified Nominees
Pacira BioSciences has communicated its confidence in its strategic direction, urging stockholders to vote for its nominated board members ahead of the 2026 Annual Meeting. The company highlighted its significant progress under the 5x30 strategy, which has led to record revenues and stock price appreciation. Additionally, the recent favorable settlement regarding EXPAREL provides a solid foundation for future growth and stability. The communication aims to reassure investors about Pacira's potential and operational strength.
Read more →PCRXPacira BioSciences Sets the Record Straight Regarding DOMA’s Misleading Statements About Pacira’s Intellectual Property Strategy
Pacira BioSciences has issued a statement defending its intellectual property strategy in response to misleading claims by DOMA Perpetual Capital Management. The company asserts the strength of its patent portfolio, especially regarding the EXPAREL franchise, and highlights successful legal outcomes, such as the reexamination of its '495 patent. Pacira encourages stockholders to support its board nominees in light of this controversy. The company aims to continue its expansion strategy while addressing the challenges posed by generic competition.
Read more →About Pacira BioSciences, Inc.
Headquarters2000 SIERRA POINT PARKWAY, BRISBANE, CA, 94005
BIOPHARMAWATCH ELITE
Trade the next PCRX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime